Drugs / Autologous CD8+ SLC45A2-specific T Lymphocytes
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03068624 | Sep 2017 → Dec 2022 | metastatic malignant neoplasm, uveal melanoma | M.D. Anderson Cancer Center | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD8+ SLC45A2-specific T Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03068624 ↗ |
| Modality | Cell therapy | “This is known as "adoptive T cell transfer" or "adoptive T cell therapy."” NCT03068624 ↗ |
| Route | Other | “via hepatic arterial infusion via central catheter” NCT03068624 ↗ |
| Target | SLC45A2 | “SLC45A2-specific cytotoxic T-lymphocytes” NCT03068624 ↗ |